Minerva Neurosciences Inc NERV
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-06-25 |
| Shares Out. | 46,590,000 |
| Website | minervaneurosciences.com/ ↗ |
| Phone | 13026365400 |
| Employees | 7 |
| Net Income | -$125.4M |
| Total Assets | $94.0M |
| Total Liabilities | $343.1M |
| Equity | -$254.0M |
About Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Minerva Neurosciences Inc is a publicly traded company under the ticker symbol NERV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)